CD19 and CD22 targeted therapy have been successful in the treatment of B cell lymphomas and rare Hairy Cell Leukemia (HCL), respectively, (Kochenderfer and Rosenberg 2013; Kreitman and Arons 2018). This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.